AAG
REGN icon

Armstrong Advisory Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Armstrong Advisory Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$25.8K Buy
34
+28
+467% +$21.2K ﹤0.01% 536
2026
Q2 		$3.74K Hold
6
– – ﹤0.01% 821
2026
Q1 		$4.64K Hold
6
– – ﹤0.01% 790
2025
Q4 		$4.63K Hold
6
– – ﹤0.01% 778
2025
Q3 		$3.37K Hold
6
– – ﹤0.01% 807
2025
Q2 		$3.15K Sell
6
-20
-77% -$11.2K ﹤0.01% 810
2025
Q1 		$18.5K Hold
26
– – ﹤0.01% 528
2024
Q4 		$18.5K Buy
26
+6
+30% +$5.04K ﹤0.01% 528
2024
Q3 		$21K Sell
20
-25
-56% -$27.8K ﹤0.01% 502
2024
Q2 		$47.3K Buy
45
+25
+125% +$24.2K ﹤0.01% 363
2024
Q1 		$17.6K Hold
20
– – ﹤0.01% 496
2023
Q4 		$17.6K Hold
20
– – ﹤0.01% 496
2023
Q3 		$16.5K Hold
20
– – ﹤0.01% 528
2023
Q2 		$14.4K Hold
20
– – ﹤0.01% 536
2023
Q1 		$16.4K Hold
20
– – ﹤0.01% 506
2022
Q4 		$14.4K Buy
+20
New +$14.8K ﹤0.01% 534

Other funds holding REGN

GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
SBWIC
Schaper Benz & Wise Investment Counsel Neenah, Wisconsin $1.51B AUM 27.44% 1-Year Est. Return
NPPM
North Point Portfolio Managers Orange Village, Ohio $595M AUM 14.89% 1-Year Est. Return
JC
Jacobs & Co San Francisco, California $1.16B AUM 34.03% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return
VC
Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

Armstrong Advisory Group's REGN Position: Q3 2026 in Review

Armstrong Advisory Group increased its Regeneron Pharmaceuticals (REGN) stake by 467% in Q3 2026, buying an estimated $21.2K and bringing the position to 34 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #536.

Armstrong Advisory Group first reported a position in REGN in Q4 2022 and has held it in 16 quarters since. The position peaked at $47.3K in Q2 2024. 54 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Armstrong Advisory Group held 34 shares of Regeneron Pharmaceuticals worth $25.8K as of Q3 2026.
  • Armstrong Advisory Group bought 28 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $21.2K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q3 2026, its #536 holding.
  • Armstrong Advisory Group first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 16 quarters since.
  • Armstrong Advisory Group's Regeneron Pharmaceuticals position peaked at $47.3K in Q2 2024.
  • 54 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Armstrong Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.